Castle Biosciences Inc

CSTLNASDAQ · USD
34.05USD-0.80 (-2.30%)
6510

Castle Biosciences Inc (CSTL) Wheel Strategy

CSTL wheel strategy scan found 8 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 54.0%.

Read more

Running a CSTL wheel strategy lets you generate consistent premium income on Castle Biosciences Inc while setting your own entry and exit prices on the underlying. Castle Biosciences Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own CSTL, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best CSTL wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on CSTL, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable CSTL wheel from a losing one.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions.

It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the CSTL wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your CSTL wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Oct 16, 202635.00$0.60$1.45-0.432815%50.7%54.0%0
Nov 20, 202630.00$0.50$1.90-0.246315%75.2%36.7%0
Jan 15, 202730.00$0.35$2.13-0.2511915%67.2%21.7%0
Apr 16, 202730.00$2.10$3.10-0.2621015%60.8%18.0%3
Nov 20, 202625.00$0.10$0.63-0.106315%93.6%14.5%0
Apr 16, 202725.00$0.45$2.03-0.1621015%76.8%14.1%6
Apr 16, 202722.50$0.30$1.53-0.1221015%84.1%11.8%5
Jan 15, 202722.50$0.15$0.45-0.0711915%92.1%6.1%0

As of September 22, 2026

Run the Wheel on CSTL With Confidence

Find the best CSTL wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial